Vera Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a VERA research report →
About the company
Vera Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of treatments for significant immunological disorders, primarily within the United States. Their leading therapeutic candidate is atacicept, a fusion protein that patients self-administer as a subcutaneous injection.
- CEO
- Gary Barrera
- IPO
- 2021
- Employees
- 152
- HQ
- Brisbane, CA, US
Price Chart
- Market Cap
- $2.96B
- P/E
- -7.44
- P/S
- 0.00
- P/B
- 5.89
- EV/EBITDA
- -8.18
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -74.86%
- ROIC
- -66.50%
- Revenue
- $0 · 0.00%
- Net Income
- $-299,615,000 · -96.92%
- EPS
- $-4.66 · -69.45%
- Op Income
- $-315,473,000
- FCF YoY
- -78.20%
- 52W High
- $56.05
- 52W Low
- $19.07
- 50D MA
- $36.17
- 200D MA
- $37.94
- Beta
- 0.95
- Avg Volume
- 1.38M
Get TickerSpark's AI analysis on VERA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 23, 26 | Fordyce Marshall | sell | 18,412 |
| Jun 23, 26 | Fordyce Marshall | sell | 88 |
| May 21, 26 | Morrison Scott W | other | 17,084 |
| May 21, 26 | Cheng Andrew | other | 17,084 |
| May 21, 26 | SEIDENBERG BETH C | other | 17,084 |
| May 21, 26 | Oliger Christy J. | other | 17,084 |
| May 21, 26 | Meyers James R | other | 17,084 |
| May 21, 26 | Hall Kimball | other | 17,084 |
| May 21, 26 | MORRISSEY MICHAEL | other | 17,084 |
| May 21, 26 | ENRIGHT PATRICK G | other | 17,084 |
Our VERA coverage
Recent articles, reports, and earnings notes.
No research on VERA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate VERA report →Similar companies
Peers in the same neighborhood.